CAMP4 to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences: